Correction: The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
C. Hage, V. Rausch, N. Giese, T. Giese, F. Schönsiegel, S. Labsch, C. Nwaeburu, J. Mattern, J. Gladkich, I. Herr
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPancreatic and Hepatic Oncology Research · Liver physiology and pathology · FOXO transcription factor regulation
Correction to: Cell Death and Disease 10.1038/cddis.2013.158, published online 09 May 2013
An image was mistakenly switched in Figure 5B during graphical figure assembly. I would like to emphasize that this image mix-up does not affect the quantitative analysis and the statement of our manuscript in any way. The authors would like to apologize for the confusion.